The number of confirmed COVID-19 cases in the Philippines went up to 391,809 after 2,092 new infections were reported by the Department of Health Friday.
The newly reported cases pushed the number of active cases or patients still undergoing treatment to 34,374. Majority or 83.6 percent of the active cases have mild symptoms, 9.8 percent are asymptomatic, 4.2 percent are in critical condition, and 2.4 percent have severe symptoms.
Davao City recorded the highest number of new cases with 129, Quezon City with 100, Quezon with 83, Northern Samar with 82, and Cavite with 80, the DoH said.
Fifty-two patients succumbed to the disease, taking the death toll to 7,461. Meanwhile, recoveries rose to 349,974 with 462 new survivors.
Among healthcare workers, a total of 11,297 tested positive for COVID-19 as of Nov. 4. Of these, 10,958 have recovered, 71 have died, and 268 are active cases, the DoH said.
Of the active cases, 129 are mild cases, 105 are asymptomatic, 23 are in severe condition, and 11 are in critical condition, the DoH noted.
DoH Undersecretary Maria Rosario Vergeire said that the protocols for the clinical trial of Japanese anti-flu drug Avigan is being revised in order to recruit more patients to participate in this initiative.
“We will strategize and revise the protocol of our clinical trial team so that we can expand the recruitment of patients and be able to reach 100 patients,” said Vergeire.
Currently, they have only recruited four patients, the Health official said.
“Para sa mga mild lang na mga kaso (ito). Alam naman natin ngayon, wala na masyado na aadmit na mga mild sa ating hospital at dahil sa patuloy na pagbaba ng kaso hindi na tayo masyado nakakakita ng pasyente na ganito (mild case) sa ating mga hospital,” said Vergeire.
“So nagkakaroon ng challenge sa ating clinical trial for Avigan,” she added.
With this development, the conduct of clinical trials for Avigan will be delayed further. The Philippines received Avigan tablets from Japan last August intended for 100 patients.